Navigation Links
Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth

Socio-economic benefits becoming evident among resource-poor farmers

MANILA, Philippines, Feb. 13 /PRNewswire/ -- After a dozen years of commercialization, biotech crops are still gaining ground with another year of double-digit growth and new countries joining the list of supporters, according to a report released today by the International Service for the Acquisition of Agri-biotech Applications (ISAAA). In 2007, biotech crop area grew 12 percent or 30.3 million acres to reach 282.3 million acres, the second highest area increase in the past five years.

In addition to planting more biotech acres, farmers are quickly adopting varieties with more than one biotech trait. These "trait acres" grew at a swift 22 percent, or 64 million acres, to reach 354.9 million acres -- more than double the area increase of 30.3 million acres. New crops were also added to the list as China reported 250,000 biotech poplar trees planted. The insect-resistant trees can contribute to reforestation efforts.

Further, 2 million more farmers planted biotech crops last year to total 12 million farmers globally enjoying the advantages from the improved technology. Notably, 9 out of 10, or 11 million of the benefiting farmers, were resource-poor farmers, exceeding the 10-million milestone for the first time. In fact, the number of developing countries (12) planting biotech crops surpassed the number of industrialized countries (11), and the growth rate in the developing world was three times that of industrialized nations (21 percent compared to 6 percent.)

"With increasing food prices globally, the benefits of biotech crops have never been more important," said Clive James, chairman and founder of ISAAA and the report's author. "Already those farmers who began adopting biotech crops a few years ago are beginning to see socio-economic advantages compared to their peers who haven't adopted the crops. If we are to achieve the Millennium Development Goals (MDGs) of cutting hunger and poverty in half by 2015, biotech crops must play an even bigger role in the next decade."

According to the report, biotech crops have delivered unprecedented benefits that contribute toward the MDGs, particularly in countries like China, India and South Africa. The potential in the second decade of biotech crop commercialization (2006-2015) is enormous.

Studies in India and China show Bt cotton has increased yields by up to 50 percent and 10 percent, respectively, and reduced insecticide use in both countries up to 50 percent or more. In India, growers increased income up to $250 or more per hectare, increasing farmer income nationally from $840 million to $1.7 billion last year. Chinese farmers saw similar gains with incomes growing an average of $220 per hectare, or more than $800 million nationally. Importantly, these studies showed strong farmer confidence in the crops with 9 of 10 Indian farmers replanting biotech cotton year on year, and 100 percent of Chinese farmers choosing to continue utilizing the technology.

While these types of economic benefits are well substantiated, the socio-economic benefits associated with biotech crops are starting to emerge. A study of 9,300 Bt cotton and non-Bt cotton-growing households in India indicated that women and children in Bt cotton households have slightly more access to social benefits than non-Bt cotton growers. These include slight increases in pre-natal visits, assistance with at-home births, higher school enrollment for children and a higher proportion of children vaccinated.

Rosalie Ellasus, a widowed mother of 3 children, found similar benefits, choosing farming as a way to support her family. "With the extra income generated from biotech maize, investing in farming made sense and allowed me to earn more than the medical technology field I was trained in," she said. "The biotech maize gave me peace of mind and meant less time monitoring for pests. With stack corn, I also incur savings on cultivation and weeding costs. With the added income, I have been able to send all my children to college."

"It's these types of benefits that will make crop biotechnology a vital tool in achieving the U.N. Millennium Development Goals of cutting hunger and poverty in half and ensuring a more sustainable agriculture in the future," James said. "To reach these goals, a continued broadening and deepening of biotech crop use is crucial to meeting food, feed, fiber and fuel needs in the future."

In 2007, the United States, Argentina, Brazil, Canada, India and China continued to be the principal adopters of biotech crops globally. While the United States continues to be the largest user of the technology, its biotech crop area represents a declining share of the global area due to a broadening adoption.

"With a dozen years of accumulated knowledge and significant economic, environmental and socio-economic benefits, biotech crops are poised for even greater growth in coming years, particularly in developing countries that have the greatest need for this technology," James said.

According to the report, Burkina Faso, Egypt and possibly Vietnam are the next mostly likely countries to approve biotech crops. Australia is field-testing drought-tolerant wheat and two states recently lifted a four-year ban on biotech canola. Finally, countries like India recognize the importance of using biotechnology to make the country self-sufficient in food grains, including rice, wheat and oil seed production with the first biotech food crop, biotech eggplant, expecting approval in the near-term.

"I predict the number of biotech countries, crops, traits, area and farmers will all grow substantially in the second decade of adoption," James said. "More developing countries are likely to approve the technology as it's now possible to design regulatory systems that are rigorous without being onerous given their limited resources. The current delay in timely approvals of biotech crops like golden rice with benefits for millions is a moral dilemma where the demands of regulatory systems have often become the end and not the means."

The report is entirely funded by the Rockefeller Foundation, a U.S.-based philanthropic organization associated with the Green Revolution; Ibercaja, one of the largest Spanish banks headquartered in the maize growing region of Spain; and the Bussolera-Branca Foundation from Italy, which supports the open-sharing of knowledge on biotech crops to aid decision-making by global society. For more information or the executive summary, log on to

The International Service for the Acquisition of Agri-biotech Applications (ISAAA) is a not-for-profit organization with an international network of centers designed to contribute to the alleviation of hunger and poverty by sharing knowledge and crop biotechnology applications. Clive James, chairman and founder of ISAAA, has lived and/or worked for the past 25 years in the developing countries of Asia, Latin America and Africa, devoting his efforts to agricultural research and development issues with a focus on crop biotechnology and global food security.

SOURCE International Service for the Acquisition of Agri-biotech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
2. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
3. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
4. First documented case of pest resistance to biotech cotton
5. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
6. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
7. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
11. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):